Stacy Amin spoke with Bloomberg Law about a move to repeal a Michigan law that once gave pharmaceutical companies a near-total defense against claims of injuries associated with products approved by the Food and Drug Administration (FDA).
“It is counterproductive to [FDA’s] goal of promoting and protecting the public health to have state-level litigation challenging products that FDA has reviewed extensively and determined meet FDA’s gold standards,” Stacy said.
Read the full article (subscription required).